Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03148808 · ClinicalTrials.gov registry record · Phase 1
Natural Vascular Scaffold (NVS) Therapy
A Phase 1 study, sponsored by Alucent Biomedical.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT03148808 is a Phase 1 study that has completed, run by Alucent Biomedical. The registered enrollment target is 3 participants.
The verdict
NCT03148808, a Phase 1 study, has completed, sponsored by Alucent Biomedical.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The NVS Therapy is being studied to evaluate the safety and efficacy of retention of acute luminal gain, leading to acute hemodynamic improvement in superficial femoral and popliteal arteries with reference vessel diameters between 3.5 and 7.0 mm and lesion lengths between 36 and 96mm. The system is intended for use in patients with de novo lesions in the superficial femoral and proximal popliteal arteries.
Interventions
- COMBINATION_PRODUCT NVS Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-05-25 |
| Est. Completion | 2018-10-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03148808
The ClinicalTrials.gov registry entry for NCT03148808 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alucent Biomedical, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NVS Therapy is the first listed.
NCT03148808 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03148808 about?
NCT03148808 is a clinical study titled "Natural Vascular Scaffold (NVS) Therapy". The NVS Therapy is being studied to evaluate the safety and efficacy of retention of acute luminal gain, leading to acute hemodynamic improvement in superficial femoral and popliteal arteries with reference vessel diameters between 3.5 and 7.0 mm and lesion lengths between 36 and 96mm. The system is...
What is the current status of trial NCT03148808?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2017-05-25. Estimated completion is 2018-10-29.
What interventions are being tested in trial NCT03148808?
The interventions under investigation include: NVS Therapy (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03148808?
This trial is sponsored by Alucent Biomedical, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.